nach oben

Erschienen in:

21.02.2022 | Leitlinie

Die neue internationale Leitlinie zur Diagnostik und Behandlung der chronischen inflammatorischen demyelinisierenden Polyradikuloneuropathie (CIDP)

verfasst von: A. Grimm, P. Baum, J. Klehmet, Prof. Dr. H. C. Lehmann, K. Pitarokoili, T. Skripuletz, J. Schmidt, M.-S. Yoon, C. Sommer

Erschienen in: DGNeurologie | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Auszug

Die chronisch inflammatorische demyelinisierende Polyradikuloneuropathie (CIDP) ist eine autoimmun vermittelte, entzündliche Erkrankung des peripheren Nervensystems. Die Prävalenz wird auf 0,8–8,9 pro 100.000 Personen pro Jahr geschätzt [1]. Sie kann in jedem Lebensalter auftreten, am häufigsten ist sie jedoch zwischen dem 40. und 60. Lebensjahr. Männer sind häufiger davon betroffen. Eine Manifestation ist auch im Säuglings- und Kindesalter möglich [2]. …

Broers MC, Bunschoten C, Nieboer D et al (2019) Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology 52:161–172. https://doi.org/10.1159/000494291CrossRefPubMed

Nevo Y, Pestronk A, Kornberg AJ et al (1996) Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology 47:98–102. https://doi.org/10.1212/wnl.47.1.98CrossRefPubMed

Breiner A, Brannagan TH (2014) Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 50:40–46. https://doi.org/10.1002/mus.24088CrossRefPubMed

Joint Task Force of the EFNS and the PNS (2005) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 10:220–228. https://doi.org/10.1111/j.1085-9489.2005.10302.xCrossRef

Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. J Peripher Nerv Syst 15:185–195. https://doi.org/10.1111/j.1529-8027.2010.00278.xCrossRef

Chaudhary UJ, Rajabally YA (2021) Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy. J Neurol 268:1366–1373. https://doi.org/10.1007/s00415-020-10287-7CrossRefPubMed

Allen JA, Lewis RA (2015) CIDP diagnostic pitfalls and perception of treatment benefit. Neurology 85:498–504. https://doi.org/10.1212/WNL.0000000000001833CrossRefPubMed

Sommer C (2018) Therapie akuter und chronischer immunvermittelter Neuropathien und Neuritiden, S2e-Leitlinie. In: Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Hrsg.). www.dgn.org/leitlinien. Zugegriffen: 26. Nov. 2021

Ruts L, Drenthen J, Jacobs BC et al (2010) Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 74:1680–1686. https://doi.org/10.1212/WNL.0b013e3181e07d14CrossRefPubMed

10.

Henderson RD, Sandroni P, Wijdicks EFM (2005) Chronic inflammatory demyelinating polyneuropathy and respiratory failure. J Neurol 252:1235–1237. https://doi.org/10.1007/s00415-005-0848-2CrossRefPubMed

11.

Stamboulis E, Katsaros N, Koutsis G et al (2006) Clinical and subclinical autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 33:78–84. https://doi.org/10.1002/mus.20438CrossRefPubMed

12.

Doneddu PE, Cocito D, Manganelli F et al (2019) Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry 90:125–132. https://doi.org/10.1136/jnnp-2018-318714CrossRefPubMed

13.

Katz JS, Saperstein DS, Gronseth G et al (2000) Distal acquired demyelinating symmetric neuropathy. Neurology 54:615–620. https://doi.org/10.1212/wnl.54.3.615CrossRefPubMed

14.

Maisonobe T, Chassande B, Vérin M et al (1996) Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients. J Neurol Neurosurg Psychiatry 61:36–42. https://doi.org/10.1136/jnnp.61.1.36CrossRefPubMedPubMedCentral

15.

Van den Berg-Vos RM, Van den Berg LH, Franssen H et al (2000) Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity? Neurology 54:26–32. https://doi.org/10.1212/wnl.54.1.26CrossRefPubMed

16.

Saperstein DS, Amato AA, Wolfe GI et al (1999) Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve 22:560–566. https://doi.org/10.1002/(sici)1097-4598(199905)22:5<560::aid-mus2>3.0.co;2-qCrossRefPubMed

17.

Thomas PK, Claus D, Jaspert A et al (1996) Focal upper limb demyelinating neuropathy. Brain J Neurol 119(Pt 3):765–774. https://doi.org/10.1093/brain/119.3.765CrossRef

18.

Donaghy M, Mills KR, Boniface SJ et al (1994) Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 57:778–783. https://doi.org/10.1136/jnnp.57.7.778CrossRefPubMedPubMedCentral

19.

Yeh WZ, Dyck PJ, van den Berg LH et al (2020) Multifocal motor neuropathy: controversies and priorities. J Neurol Neurosurg Psychiatry 91:140–148. https://doi.org/10.1136/jnnp-2019-321532CrossRefPubMed

20.

Oh SJ, Joy JL, Kuruoglu R (1992) “Chronic sensory demyelinating neuropathy”: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry 55:677–680. https://doi.org/10.1136/jnnp.55.8.677CrossRefPubMedPubMedCentral

21.

Van den Bergh PYK, van Doorn PA, Hadden RDM et al (2021) European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst 26:242–268. https://doi.org/10.1111/jns.12455CrossRefPubMed

22.

Van den Bergh PYK, Piéret F (2004) Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 29:565–574. https://doi.org/10.1002/mus.20022CrossRefPubMed

23.

Goedee HS, Jongbloed BA, van Asseldonk J‑TH et al (2017) A comparative study of brachial plexus sonography and magnetic resonance imaging in chronic inflammatory demyelinating neuropathy and multifocal motor neuropathy. Eur J Neurol 24:1307–1313. https://doi.org/10.1111/ene.13380CrossRefPubMed

24.

Herraets IJT, Goedee HS, Telleman JA et al (2020) Nerve ultrasound improves detection of treatment-responsive chronic inflammatory neuropathies. Neurology 94:e1470–e1479. https://doi.org/10.1212/WNL.0000000000008978CrossRefPubMed

25.

Härtig F, Ross M, Dammeier NM et al (2018) Nerve ultrasound predicts treatment response in chronic inflammatory demyelinating polyradiculoneuropathy—a prospective follow-up. Neurotherapeutics 15:439–451. https://doi.org/10.1007/s13311-018-0609-4CrossRefPubMedPubMedCentral

26.

Kerasnoudis A, Pitarokoili K, Gold R, Yoon M‑S (2015) Bochum ultrasound score allows distinction of chronic inflammatory from multifocal acquired demyelinating polyneuropathies. J Neurol Sci 348:211–215. https://doi.org/10.1016/j.jns.2014.12.010CrossRefPubMed

27.

Grimm A, Axer H, Heiling B, Winter N (2018) Nerve ultrasound normal values—readjustment of the ultrasound pattern sum score UPSS. Clin Neurophysiol 129:1403–1409. https://doi.org/10.1016/j.clinph.2018.03.036CrossRefPubMed

28.

Grimm A‑S, Schubert C, Grimm A et al (2020) Normative observational nerve ultrasound values in school-age children and adolescents and their application to hereditary neuropathies. Front Neurol 11:303. https://doi.org/10.3389/fneur.2020.00303CrossRefPubMedPubMedCentral

29.

Rajabally YA, Nicolas G, Piéret F et al (2009) Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study. J Neurol Neurosurg Psychiatry 80:1364–1368. https://doi.org/10.1136/jnnp.2009.179358CrossRefPubMed

30.

Rajabally YA, Attarian S (2018) Chronic inflammatory demyelinating polyneuropathy and malignancy: a systematic review. Muscle Nerve 57:875–883. https://doi.org/10.1002/mus.26028CrossRefPubMed

31.

Liberatore G, Manganelli F, Cocito D et al (2020) Relevance of diagnostic investigations in chronic inflammatory demyelinating poliradiculoneuropathy: data from the Italian CIDP database. J Peripher Nerv Syst. https://doi.org/10.1111/jns.12378CrossRefPubMed

32.

Kulkarni GB, Mahadevan A, Taly AB et al (2010) Sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy: are supportive pathologic criteria useful in diagnosis? Neurol India 58:542–548. https://doi.org/10.4103/0028-3886.68673CrossRefPubMed

33.

Sommer CL, Brandner S, Dyck PJ et al (2010) Peripheral Nerve Society Guideline on processing and evaluation of nerve biopsies. J Peripher Nerv Syst 15:164–175. https://doi.org/10.1111/j.1529-8027.2010.00276.xCrossRefPubMed

34.

Xu M, Pinto M, Sun C et al (2019) Expanded teased nerve fibre pathological conditions in disease association. J Neurol Neurosurg Psychiatry 90:138–140. https://doi.org/10.1136/jnnp-2018-319077CrossRefPubMed

35.

Sommer C, Koch S, Lammens M et al (2005) Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology 65:1924–1929. https://doi.org/10.1212/01.wnl.0000188879.19900.b7CrossRefPubMed

36.

Vallat J‑M, Tabaraud F, Magy L et al (2003) Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evaluation of eight cases. Muscle Nerve 27:478–485. https://doi.org/10.1002/mus.10348CrossRefPubMed

37.

Dahlin LB, Eriksson KF, Sundkvist G (1997) Persistent postoperative complaints after whole sural nerve biopsies in diabetic and non-diabetic subjects. Diabet Med 14:353–356. https://doi.org/10.1002/(SICI)1096-9136(199705)14:5<353::AID-DIA343>3.0.CO;2-ECrossRefPubMed

38.

Theriault M, Dort J, Sutherland G, Zochodne DW (1998) A prospective quantitative study of sensory deficits after whole sural nerve biopsies in diabetic and nondiabetic patients. Surgical approach and the role of collateral sprouting. Neurology 50:480–484. https://doi.org/10.1212/wnl.50.2.480CrossRefPubMed

39.

IJpma FFA, Nicolai J‑PA, Meek MF (2006) Sural nerve donor-site morbidity: thirty-four years of follow-up. Ann Plast Surg 57:391–395. https://doi.org/10.1097/01.sap.0000221963.66229.b6CrossRefPubMed

40.

Hilton DA, Jacob J, Househam L, Tengah C (2007) Complications following sural and peroneal nerve biopsies. J Neurol Neurosurg Psychiatry 78:1271–1272. https://doi.org/10.1136/jnnp.2007.116368CrossRefPubMedPubMedCentral

41.

Ducic I, West J (2009) A modified approach to sural nerve biopsy: minimizing complications. Ann Plast Surg 62:220–222. https://doi.org/10.1097/SAP.0b013e31817e9c8dCrossRefPubMed

42.

Liberatore G, De Santis T, Doneddu PE et al (2020) Clinical reasoning: a case of COVID-19 associated pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Neurology. https://doi.org/10.1212/WNL.0000000000010817CrossRefPubMed

43.

Querol L, Rojas-García R, Diaz-Manera J et al (2015) Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm 2:e149. https://doi.org/10.1212/NXI.0000000000000149CrossRefPubMedPubMedCentral

44.

Querol L, Nogales-Gadea G, Rojas-Garcia R et al (2014) Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 82:879–886. https://doi.org/10.1212/WNL.0000000000000205CrossRefPubMedPubMedCentral

45.

Querol L, Devaux J, Rojas-Garcia R, Illa I (2017) Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nat Rev Neurol 13:533–547. https://doi.org/10.1038/nrneurol.2017.84CrossRefPubMed

46.

Vural A, Doppler K, Meinl E (2018) Autoantibodies against the node of Ranvier in seropositive chronic inflammatory demyelinating polyneuropathy: diagnostic, pathogenic, and therapeutic relevance. Front Immunol 9:1029. https://doi.org/10.3389/fimmu.2018.01029CrossRefPubMedPubMedCentral

47.

Miura Y, Devaux JJ, Fukami Y et al (2015) Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain J Neurol 138:1484–1491. https://doi.org/10.1093/brain/awv054CrossRef

48.

Doppler K, Appeltshauser L, Wilhelmi K et al (2015) Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin‑1 autoantibodies. J Neurol Neurosurg Psychiatry 86:720–728. https://doi.org/10.1136/jnnp-2014-309916CrossRefPubMed

49.

Oaklander AL, Lunn MP, Hughes RA et al (2017) Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev 1:CD10369. https://doi.org/10.1002/14651858.CD010369.pub2CrossRefPubMed

50.

van Schaik IN, Bril V, van Geloven N et al (2018) Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 17:35–46. https://doi.org/10.1016/S1474-4422(17)30378-2CrossRefPubMed

51.

Lehmann HC, Hartung H‑P, Hetzel GR et al (2006) Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol 63:1066–1071. https://doi.org/10.1001/archneur.63.8.1066CrossRefPubMed

52.

Eftimov F, Winer JB, Vermeulen M et al (2013) Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001797.pub3CrossRefPubMed

53.

Dyck PJ, Litchy WJ, Kratz KM et al (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838–845. https://doi.org/10.1002/ana.410360607CrossRefPubMed

54.

Kuitwaard K, Hahn AF, Vermeulen M et al (2015) Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 86:1331–1336. https://doi.org/10.1136/jnnp-2014-309042CrossRefPubMed

55.

Hadden RD, Sharrack B, Bensa S et al (1999) Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 53:57–61. https://doi.org/10.1212/wnl.53.1.57CrossRefPubMed

56.

Hughes RAC, Gorson KC, Cros D et al (2010) Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 74:651–657. https://doi.org/10.1212/WNL.0b013e3181d1a862CrossRefPubMed

Titel: Die neue internationale Leitlinie zur Diagnostik und Behandlung der chronischen inflammatorischen demyelinisierenden Polyradikuloneuropathie (CIDP)
verfasst von: A. Grimm
P. Baum
J. Klehmet
Prof. Dr. H. C. Lehmann
K. Pitarokoili
T. Skripuletz
J. Schmidt
M.-S. Yoon
C. Sommer
Publikationsdatum: 21.02.2022
Verlag: Springer Medizin
Erschienen in: DGNeurologie / Ausgabe 2/2022
Print ISSN: 2524-3446
Elektronische ISSN: 2524-3454
DOI: https://doi.org/10.1007/s42451-022-00413-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Die neue internationale Leitlinie zur Diagnostik und Behandlung der chronischen inflammatorischen demyelinisierenden Polyradikuloneuropathie (CIDP)

Auszug

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Position der therapeutischen Apherese in der Leitlinie zur Diagnose und Therapie der multiplen Sklerose, Neuromyelitis-optica-Spektrum-Erkrankungen und MOG-IgG-assoziierten Erkrankungen

CME: Diagnostik und Therapie der Neuroborreliose

Hoher Hirndruck und Stauungspapillen – die Antwort lag im Liquor

Anti-NMDA(N-Methyl-D-Aspartat)-Rezeptor-Enzephalitis bei kleinzelligem Bronchialkarzinom mit schwerer autonomer Beteiligung in Form einer Hypothermie

Plötzliche Starrheit und Spasmen in den Beinen

Fünf typische Polyneuropathieformen – So klären Sie die Ursache ab

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie